News, References & Resources

IDbyDNA Improves Analytical Performance and User Experience of Its Explify Platform and Respiratory and Urinary Pathogen ID/AMR Panels

With IDbyDNA’s latest software update to the Explify® Platform, labs can now take their NGS analysis of respiratory and urinary samples to the next level with improved sample management, strengthened user management controls, an enhanced total AMR picture and detection of the latest SARS-CoV-2 variants.

IDbyDNA Receives Second-Year Funding to Continue Participation in DARPA-funded DIGET Program

Awarded continued funding by MRIGlobal, IDbyDNA will continue to support DARPA’s “Detect it With Gene Editing Technologies” (DIGET) program focused on developing a next-generation, battlefield-tested device that delivers improved diagnostic testing of infectious disease threats.

MedCity News: The Diagnostic Dilemma of Co-Infections Requires Novel Solutions

Co-infections are common in patients with COVID-19 and are associated with a 3.3-fold higher risk of death. In a MedCity News article, Amy Hanson, PharmD, outlines how Precision Metagenomics offers better diagnostic testing to identify pathogens otherwise evading detection.

The Tech Tribune Awards IDbyDNA As One of the 2022 Best Tech Startups in Salt Lake City

Based on revenue potential, leadership team, product traction and competitive landscape, The Tech Tribune’s editorial team identified IDbyDNA as one of the very best tech startups across renowned tech hubs in the United States.

ASM Clinical Virology Symposium (CVS)

May 1-4, 2022 IDbyDNA is changing the paradigm in infectious disease and AMR marker testing by applying the power of…

European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

IDWeek

October 20-22, 2022

Detection of Neisseria gonorrhoeae from Joint Aspirate by Metagenomic Sequencing in Disseminated Gonococcal Infection

Journal of the Infectious Diseases Pediatric Society, April 2021

Added Diagnostic Utility of Clinical Metagenomics for the Diagnosis of Pneumonia in Immunocompromised Adults

Chest, April 2021

Metagenomic Next-Generation Sequencing for Pathogen Detection and Transcriptomic Analysis in Pediatric Central Nervous System Infections

Open Forum Infectious Diseases, March 2021

Metagenomic Sequencing and Evaluation of the Host Response in the Pediatric Aerodigestive Population

Pediatric Pulmonology, December 2020

Precision Metagenomics Outperforms Conventional Urine Culture in Detecting Clinically Relevant Uropathogens

Urinary Tract Infections (UTI) are among the most common community-acquired infections. Per current guidelines, treatment is informed by urine culture,…

Quantification of SARS-CoV-2 by Precision Metagenomics

The Respiratory Pathogen ID/AMR Panel (RPIP)* allows detection, quantification, and classification of SARS-CoV-2. RPIP-based and qPCR-based VLs were strongly correlated…

Leveraging Clinical Metagenomic Testing Against SARS-CoV-2

Performance of Next Generation Sequencing in Isolating a Pathogen in Pediatric Osteoarticular Infections

Know Your Organism – How the Use of Precision Medicine in Infectious Diseases Can Save Lives

Podcast

Profiling COVID-19, Flu and Other Infectious Diseases through Precision Metagenomics

Pathogen genomic profiling informs pathogen discovery, real-time monitoring, vaccine development, and infection prevention, but involves specialized laboratories. Precision Metagenomics provides…

NGS vs. Culture – Weill Cornell Research Investigating the Accuracy of Pathogen Detection Using the Respiratory Pathogen ID/AMR Panel (RPIP)*

Webinar

From Principles to Practice: How Can Metagenomics Inform Patient Care

CME

Understanding Susceptibility and Response to SARS-CoV-2 Infection in Children: A Metagenomics Approach

Product: Explify Respiratory Pathogen ID/AMR Panel (RPIP)

Parallel Detection and Variant Characterization of SARS-CoV-2 Through Precision Metagenomics

Product: Explify Respiratory Pathogen ID/AMR Panel (RPIP)

Healthy Volunteer Study: Next-Generation Sequencing-based Analysis of the Urine of Asymptomatic Individuals

Product: Explify Urinary Pathogen ID/AMR Panel (UPIP)

Precision Metagenomics for Uropathogen Identification and Antimicrobial Resistance Prediction in Adults with Signs of Urinary Tract Infection

Product: Explify Urinary Pathogen ID/AMR Panel (UPIP)

Mycoplasma hominis Pneumonia Diagnosed by Next Generation Sequencing (Explify)

Explify® Respiratory detected Mycoplasma hominis in an adolescent, immunocompromised female with severe respiratory distress and lung opacities who had negative standard of care and plasma cell-free DNA tests. She improved with directed treatment.

COVID-19 Diagnosed by Next Generation Sequencing (Explify)

Explify® Respiratory pathogen detection identified SARS-CoV-2 in an elderly patient presenting with fall-related trauma, lung opacities, and hypoxia.

Prevotella pleuriditis Infection Diagnosed in a 12-year-old Male With Progressive Pleurisy and Pneumonia Complicated by Pleural Effusion

A 12-year-old male with type II diabetes presenting with pleurisy and lung infiltrates failed to respond to multiple antibiotics as his condition worsened. Explify® Respiratory identified a rare anaerobic bacterium, Prevotella pleuriditis, in his pleural fluid, and the patient improved on directed therapy.

Pulmonary Coccidioidomycosis Diagnosed by Next-Generation Sequencing (Explify) in an Adolescent with Type 1 Diabetes

An adolescent male admitted to a Texas hospital for ketoacidosis co-presented with productive cough with hemoptysis and lung opacities. Tests for TB, invasive fungi, and next-generation sequencing of plasma cell-free DNA were negative. Explify® Respiratory identified Coccidioides immitis in sputum.

Analytical Performance of the Respiratory Pathogen ID/AMR Panel

IDbyDNA and Illumina App Note, February 2021

Comprehensive and Rapid Detection of Respiratory Pathogens and Associated Resistance Genes Using the MiniSeq™ System

IDbyDNA and Illumina App Note, October 2020

Comprehensive Workflow for Detecting Coronavirus Using Illumina Benchtop Systems

Illumina App Note, April 2020